The more favorable outcomes associated with the HER2-low status in Liu et al.’s (2025) TNBC cohort, compared to the less favorable outcomes in our broader cohort, underscore the need for further research to elucidate the complex interplay between HER2-low expression and other tumor characteristics in predicting prognosis and treatment response [30]. The gene discussed is ERBB2; the disease is neoplasm.